Array Biopharma announced a partnership this morning with Pierre Fabre, a French company, with a $30 up front payment. an upfront payment of $30 million and
"retains exclusive commercialization rights for binimetinib and encorafenib in the United States, Canada, Japan, Korea and Israel. Pierre Fabre will have exclusive rights to commercialize both products in all other countries, including Europe, Asia and Latin America. Array is entitled to receive up to $425 million if certain development and commercialization milestones are achieved, and is eligible for robust, tiered double-digit royalties. Array and Pierre Fabre have agreed to split future development costs on a 60:40 basis (Array:Pierre Fabre) with initial funding committed for new clinical trials in colorectal cancer and melanoma. All ongoing binimetinib and encorafenib clinical trials remain substantially funded through completion by Novartis."
The stock sold off, currently down 4.5% at $4.20.
There remains a large value gap which needs to close, but they can take it down much easier than it will come back up. The remaining days this week should allow for some truth and repair to issue forth.
I picked up 2,000 shares today at 3.43-3.45 in my daughter's accounts. I spent time over the weekend going over the presentations on GSO and the recent 10-Q. I like that they are going after orphan diseases, when they get to commercialization stage, with orphan drugs you aren't under the oversight by PBM's as to your drug pricing. That's where HZNP has had headline risk in the current climate of drug pricing, and the recent flap they've had with ESRX. Orphan bypasses all that. Did you see where Dermatomyositis only has an incidence of 3-5 patients per 1 million of population? That comes down to 1535 potential patients in the US pegging population at 290 million.
That's a very big drop, over a delay too, hard to fathom that kind of drop for just a delay unless the market it considering the delay to be forecasting failed approval.
Frank, what's with the weakness here heading into ASH? Got a clue? Holding mine, from your postings my guess is you have either sold out here, or reduced your position in favor of IDRA which is looking much stronger than here.
Take this discussion off this board over to Twitter or start your own blog, we have problems in this world, yes, but this isn't the forum where you can effect change or even find a receptive audience.
Sentiment: Strong Buy
Very rare (extremely rare) disease. "Dermatomyositis affects both children and adults, but tends to affect females more often than it affects males. In the United States, the incidence of DM is estimated at 5.5 cases per million people (Callen, 2002). If there are approximately 290 million people in the United States, then about 1595 people have this disease, making it extremely rare. The disease usually affects adults after the second decade of life (Brasington, 2003). Juvenile DM is even rarer, with average onset between 8-9 years of age (Juvenile, 1998). However some investigators found that there were two peaks of onset for females, occurring at age 6 and at age 11, whereas males usually acquired the disease prior to the age of 10 (Symmons, 1995). Again, among European ancestries, juvenile DM is about twice as common in girls than in boys. The data from Japanese and Saudi Arabian studies show the opposite effect: a 1:2 female to male ratio (Ramanan, 2002). These differences suggest that genetics must play an important role in the susceptibility of disease.
What are the symptoms of Dermatomyositis?
Skin and muscle involvement are the most common symptoms of DM, but it may affect other organ systems as well. The skin rash is generally patchy, violet discolorations on the face, neck, shoulders, upper chest, elbows, knees, knuckles, and back. The lilac, erythematous heliotrope rash generally surrounds the eyes and is highly characteristic of DM because it is rarely observed in other disorders (Callen, 2002). In other words, patients tend to look like they have “raccoon eyes.” To see heliotrope rash, go here. Another cutaneous manifestation includes Gottron's lesions, which are erythematous, scaly lesions that cover certain joints like the knees and elbows (Ranaman, 2002). Many other images pertaining to the skin rash in dermatomyositis can be seen at this site.
Muscle weakness is the most common symptom...
Sentiment: Strong Buy
Following on your point is brick and mortar retailers may suffer further as people avoid malls and turn instead to online purchases, giving a further boost to Amazon and others. That is a rock solid investment, it's already shot way up. I like my money in IDRA, which has yet to shoot way up but seems a sure bet to do so.
"no room for scientific ambiguity" EXACTLY what I was thinking but my words for this are "incontrovertible evidence". That is what I believe will be forthcoming out of their ASH presentation.
This is the kind of event that sends a shiver through world markets, hopefully not like our '911' Trade Towers attack. Futures are down sharply in sympathy with this horrific terrorist attack, according to a search I just did. Borders are being closed, the fear gauge is pegged to the max. The question and nobody knows, is how long will world markets likely to be destabilized? Sanofi being a French Company will no doubt take a hit, the healthcare sector won't be spared if the whole market is getting hit. Anyone here have further insights as to what we might expect going forward? Is this the event that causes a big market swoon where lately market worries have spiked?
Your target of $50 in five years is ultra conservative. I see twice that given the future of Actimmune in FA and further acquisitions, building on the growth of the pipeline and going into Rest of World.
This post is for entertainment purposes, the TA discussion that follows is intended for those who appreciate technical analysis and charting, I know some here could care less.
A week ago I posted that there were some very encouraging signs on the weekly chart. This move started 2 weeks ago when we opened Nov 2 @ 2.77 to today's close of 3.48, a 22% gain. The symmetrical triangle we are in began in July, 2014. The bottom line finishes right along the 200-MA which is at 2.33. The top line is presently at approximately $4.25. There are four touches on the top line (beginning in Feb-Mar 2014) and five touches on the bottom line (going back to end July 2014).
We are now headed up to another touch (or breakout through) the top line. These indicators are very bullish now 1) Two weeks of successive gains show green candles using Elder Impulse System 2) We touched the 50-MA early this week @ $3.64 3) The following indicators are making bullish crossovers of their signal lines TRIX, MACD, Slow Sto, KST, and PMO (already crossed or crossing now).
The last time a combination of these bullish crossovers happened (on the weekly chart) was the last week of November, 2014 when price moved from 2.50 to $5.29 on January 14, 2014. Does TA work? You decide, I think it gives us strong information to guide our trading and investing decisions. Looking forward to the next two months of weeks with you my fellow longs. GLAL. Jr.
Sentiment: Strong Buy
The offering was at $6. Who is selling, can curious timing? Today did we experience short attack by new owners who are shorting the shares of their newly owned Company?
Give your thesis to support your claim so we understand your statement. It looks like it's definitely on the floor but what makes you say it will go up X13 in one year?
Some law firm should open a class action suit against ES and see who else is out there wanting protection and recovery.
Ken, you can find Mike over on NVIV board, he' actively posting there. He must have sold here, you recall his post about "Flagships and Icebergs", how prophetic. Had I not sold in the 30's my year would have been wiped out. What a bad second half for our stock (yes, back in now with 14,000 shares).